(13), and others likely reflect differences in experimental paradigms, including the specific GLP-1R agonist used (short acting versus long acting, small molecule versus large molecule, etc.), the route of administration (i.p., s.c., or i.v.), dose, species studied, acute versus chronic analysis, and intrinsic shortcomings in the specific model systems used, such as lack of complete tissue specificity with Cre drivers, incomplete knockdowns, and potential developmental compensation when using constitutively active versus tamoxifen-inducible Cre systems
Here's how to choose a probiotic that actually fits GLP-1 physiology in 2026
The difference reflects population: TRIUMPH-4's osteoarthritis cohort was older and more comorbid
Collagen peptides are maintenance/prevention